News >

Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma

Melody Watson
Published: Thursday, Jul 06, 2017

Claus Garbe, MD

Claus Garbe, MD

The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate (ORR) in patients with unresected stage IIIb to IV melanoma, according to findings presented at the 7th European Post-Chicago Melanoma/Skin Cancer Meeting.

“What will be very important is to see the results of the MASTERKEY-265 study, which is a combination of pembrolizumab [Keytruda] plus T-VEC because we have to try to get immune responses in first-line treatment by combining as many treatment approaches as possible,” said Garbe. “So, I am still hoping that T-VEC will add something to that. We will probably not bring ipilimumab plus T-VEC into clinical practice but the main question will be whether we can combine it with PD-1 inhibitors or with both—with PD-1 plus CTLA-4 inhibitors in a triplet combination. And, if T-VEC can improve the outcome in our metastasized patients we will undoubtedly use it.”
Chesney J, Puzanov, Ross M, et al. Combination of talimogene laherparepvec and ipilimumab versus ipilimumab alone in unresected stage IIIB-IV melanoma: primary results from a randomized (1:1), open-label phase 2 study. Presented at: 7th European Post-Chicago Melanoma/Skin Cancer Meeting; June 29-30, 2017; Munich, Germany.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x